

# Novel approaches in the therapy of metastatic renal cell

World Journal of Urology

23, 202-212

DOI: 10.1007/s00345-004-0466-0

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytoreductive nephrectomy in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2006, 6, 1295-1304.	2.4	4
2	Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opinion on Investigational Drugs, 2006, 15, 553-561.	4.1	108
3	Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Letters, 2006, 240, 170-182.	7.2	41
5	Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics, 2006, 6, 2853-2864.	2.2	75
6	Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. Journal of Cancer Research and Clinical Oncology, 2006, 132, 137-149.	2.5	36
7	Treatment options in renal cell carcinoma: past, present and future. Annals of Oncology, 2007, 18, x25-x31.	1.2	59
8	Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. Clinical Cancer Research, 2007, 13, 697s-702s.	7.0	68
9	Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials: Fig. 1.. Clinical Cancer Research, 2007, 13, 703s-708s.	7.0	31
10	Characterization of Primary Renal Carcinoma Cultures. Urologia Internationalis, 2007, 79, 235-243.	1.3	10
12	Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. European Journal of Cancer, Supplement, 2007, 5, 4-11.	2.2	2
13	Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. European Journal of Cancer, Supplement, 2007, 5, 20-27.	2.2	4
14	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2007, 356, 115-124.	27.0	5,409
16	Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer, 2007, 7, 133.	2.6	58
17	Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World Journal of Urology, 2007, 25, 59-72.	2.2	9
18	Angiogenesis and angiogenic inhibitors in renal cell carcinoma. Current Urology Reports, 2008, 9, 26-33.	2.2	13
19	Cr�ation d�une unit� de coordination de la prise en charge des tumeurs rares du rein de l�adulte. Oncologie, 2008, 10, 437-442.	0.7	0
20	Serum biomarker discovery in renal cancer using 2�DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same?. Proteomics, 2008, 8, 5074-5085.	2.2	33
21	The burden of renal cell cancer: A retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database. European Journal of Cancer, Supplement, 2008, 6, 46-51.	2.2	5

#	ARTICLE	IF	CITATIONS
22	Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. <i>Cancer Treatment Reviews</i> , 2008, 34, 193-205.	7.7	832
23	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 232-244.	1.5	9
24	Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFN $\gamma$ in Patients with Good Prognosis Metastatic Renal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5907-5912.	7.0	26
25	Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2009, 2, 51.	2.0	30
26	Pharmacokinetics of sunitinib in hemodialysis. <i>Annals of Oncology</i> , 2009, 20, 190-192.	1.2	52
27	Prognostic markers and targeted therapies for renal cell carcinoma. <i>Future Oncology</i> , 2009, 5, 197-205.	2.4	0
28	Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4068-4075.	1.6	188
29	Phase I Trial of Sunitinib Malate plus Interferon- $\gamma$ for Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 28-33.	1.9	62
30	Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. <i>International Journal of Cancer</i> , 2009, 125, 474-482.	5.1	93
31	Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer. <i>Drug Safety</i> , 2009, 32, 717-734.	3.2	32
32	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763.	10.7	571
33	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. <i>World Journal of Urology</i> , 2010, 28, 311-317.	2.2	2
34	A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 429-38.	1.5	13
35	NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. <i>British Journal of Cancer</i> , 2010, 102, 873-882.	6.4	31
36	Management of metastatic renal cell carcinoma in patients with poor prognosis. <i>Cancer Management and Research</i> , 2010, , 123.	1.9	5
37	Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience. <i>Korean Journal of Urology</i> , 2010, 51, 450.	1.2	14
38	Combination Therapy of Interleukin-2 and Sorafenib Improves Survival Benefits and Prevents Spontaneous Pulmonary Metastasis in Murine Renal Cell Carcinoma Models. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 503-507.	1.3	6
39	A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 194-202.	1.3	133

#	ARTICLE	IF	CITATIONS
40	Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma. <i>Chemotherapy</i> , 2010, 56, 485-491.	1.6	18
41	Laparoscopic Cytoreductive Nephrectomy: A Three-Center Retrospective Analysis. <i>Journal of Endourology</i> , 2010, 24, 1451-1455.	2.1	8
42	Severe Dyspnea due to Pulmonary Metastasis of Renal Cell Carcinoma: Is Cytoreductive Surgery of Value. <i>Case Reports in Oncology</i> , 2010, 3, 339-343.	0.7	2
43	Progress in the Management of Advanced Renal Cell Carcinoma (RCC). <i>Aktuelle Urologie</i> , 2010, 41, S57-S60.	0.3	0
44	Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1005-1015.	3.3	11
45	Linkage of microRNA and Proteome-Based Profiling Data Sets: A Perspective for the Priorization of Candidate Biomarkers in Renal Cell Carcinoma?. <i>Journal of Proteome Research</i> , 2011, 10, 191-199.	3.7	11
46	Axitinib for the Management of Metastatic Renal Cell Carcinoma. <i>Drugs in R and D</i> , 2011, 11, 113-126.	2.2	130
47	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. <i>European Journal of Cancer</i> , 2011, 47, 1955-1961.	2.8	111
48	Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2592-2602.	2.8	108
49	Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2011, 37, 180-186.	1.5	5
50	Vaccines for Colorectal Cancer and Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 283-293.	2.0	6
51	Combination therapy for renal cell carcinoma: review of the clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 689-697.	0.0	0
52	Spontaneous Regression of Multiple Pulmonary Metastases After Radiofrequency Ablation of a Single Metastasis. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 424-430.	2.0	47
53	Bevacizumab in Combination with Interferon Alpha in Metastatic Renal Cell Carcinoma: The Emerging Evidence of Its Therapeutic Value. <i>Clinical Medicine Reviews in Oncology</i> , 2011, 3, 59-69.	0.0	0
54	Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. <i>Annals of Oncology</i> , 2011, 22, 794-800.	1.2	116
55	An overview of angiogenesis and renal cell carcinoma. <i>International Journal of Nutrition, Pharmacology, Neurological Diseases</i> , 2012, 2, 3.	0.5	7
56	Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-5.	0.3	4
57	Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. <i>British Journal of Cancer</i> , 2012, 107, 1665-1671.	6.4	97

#	ARTICLE	IF	CITATIONS
58	CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy. <i>International Urology and Nephrology</i> , 2012, 44, 1663-1669.	1.4	19
59	Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2012, 39, 211-231.	1.8	24
60	The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 202-208.	2.8	170
61	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1031-1037.	2.8	49
62	DDX31 Regulates the p53-HDM2 Pathway and rRNA Gene Transcription through Its Interaction with NPM1 in Renal Cell Carcinomas. <i>Cancer Research</i> , 2012, 72, 5867-5877.	0.9	35
63	Targeting the Tumor Microenvironment: Focus on Angiogenesis. <i>Journal of Oncology</i> , 2012, 2012, 1-16.	1.3	93
64	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. <i>Nature Reviews Urology</i> , 2012, 9, 147-155.	3.8	51
65	Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. <i>Medical Oncology</i> , 2012, 29, 750-754.	2.5	10
66	Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2012, 19, 796-804.	1.0	8
67	Chromophobe renal cell carcinoma: A review of an uncommon entity. <i>International Journal of Urology</i> , 2012, 19, 894-900.	1.0	85
68	Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. <i>BMC Clinical Pathology</i> , 2013, 13, 3.	1.8	15
69	Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease. <i>Journal of Translational Medicine</i> , 2013, 11, 255.	4.4	32
70	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	2.8	60
71	VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. <i>British Journal of Cancer</i> , 2013, 108, 1126-1132.	6.4	71
72	Optimal management of renal cell carcinoma in the elderly: a review. <i>Clinical Interventions in Aging</i> , 2013, 8, 433.	2.9	35
73	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.6	8
74	Erfolge und Grenzen zielgerichteter Therapien beim Nierenzellkarzinom. <i>Karger Kompass Onkologie</i> , 2014, 1, 66-74.	0.0	0
75	GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 2250-2260.	6.4	34

#	ARTICLE	IF	CITATIONS
76	Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma. Progress in Tumor Research, 2014, 41, 98-112.	0.1	8
77	Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies. PLoS ONE, 2014, 9, e114264.	2.5	35
78	Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation. International Journal of Oncology, 2014, 44, 1490-1498.	3.3	25
79	Prognostic impact of baseline serum <sc>C</sc>-reactive protein in patients with metastatic renal cell carcinoma (<sc>RCC</sc>) treated with sunitinib. BJU International, 2014, 114, 81-89.	2.5	68
80	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncology, 2014, 10, 1361-1372.	2.4	9
81	Renal cell carcinoma metastasis to the parathyroid gland: A very rare occurrence. International Journal of Surgery Case Reports, 2014, 5, 378-380.	0.6	5
82	Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?. World Journal of Urology, 2014, 32, 39-45.	2.2	9
83	Diffusion-weighted imaging of focal renal lesions: a meta-analysis. European Radiology, 2014, 24, 241-249.	4.5	116
84	Can Initial 18F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?. Nuclear Medicine and Molecular Imaging, 2014, 48, 144-152.	1.0	17
85	Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-“Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis. Clinical Genitourinary Cancer, 2014, 12, e205-e214.	1.9	33
86	Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Oncologist, 2014, 19, 51-60.	3.7	57
87	Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World Journal of Urology, 2014, 32, 615-622.	2.2	18
88	High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience. Urology, 2014, 83, 1129-1134.	1.0	24
89	Expression profiling of metastatic renal cell carcinoma using gene set enrichment analysis. International Journal of Urology, 2014, 21, 46-51.	1.0	15
90	Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study. Forum of Clinical Oncology, 2015, 6, 23-27.	0.2	1
91	Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells. PLoS ONE, 2015, 10, e0145769.	2.5	20
92	Potentials of Interferon Therapy in the Treatment of Pancreatic Cancer. Journal of Interferon and Cytokine Research, 2015, 35, 327-339.	1.2	21
93	Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis. Clinical Genitourinary Cancer, 2015, 13, 280-286.	1.9	21

#	ARTICLE	IF	CITATIONS
94	Axitinib in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 499-507.	2.4	13
95	Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib. European Radiology, 2015, 25, 375-379.	4.5	13
96	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clinical Cancer Research, 2015, 21, 1925-1934.	7.0	67
97	Axitinib: A Review in Advanced Renal Cell Carcinoma. Drugs, 2015, 75, 1903-1913.	10.9	40
98	Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma. Oncology Letters, 2016, 12, 1265-1270.	1.8	12
99	An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures. Scientific Reports, 2016, 6, 33398.	3.3	31
100	Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e575-e583.	1.9	10
101	Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. International Urology and Nephrology, 2016, 48, 1253-1260.	1.4	12
102	Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. Journal of Neurosurgery: Spine, 2016, 25, 766-774.	1.7	51
103	Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. Nature Communications, 2016, 7, 10656.	12.8	81
104	The effect of information on preferences for treatments of metastatic renal cell carcinoma. Current Medical Research and Opinion, 2016, 32, 1827-1838.	1.9	8
105	Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Current Medical Research and Opinion, 2016, 32, 741-747.	1.9	12
106	A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent. Clinical Genitourinary Cancer, 2016, 14, 271-276.	1.9	15
107	Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER Medicare Database Analysis. Clinical Genitourinary Cancer, 2017, 15, e573-e582.	1.9	53
108	Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4 cm)? A propensity score matched study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 379-385.	1.6	36
109	Metastatic Renal Cell Carcinoma to Jejunum: An Unusual Case Presentation. Urology Case Reports, 2017, 13, 34-36.	0.3	4
110	Diagnostic and prognostic value of scavenger receptor class B type 1 in clear cell renal cell carcinoma. Tumor Biology, 2017, 39, 101042831769911.	1.8	11
111	Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma. Oncology Research and Treatment, 2017, 40, 707-710.	1.2	7



#	ARTICLE	IF	CITATIONS
112	Engrailedâ€™2 promoter hyperâ€™methylation is associated with its downregulation in clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 6888-6894.	1.8	4
113	Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 454-460.	1.0	0
114	ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 222.	2.6	6
115	Testicular Metastasis from Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2017, 10, 388-391.	0.7	8
116	Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. <i>Translational Research</i> , 2017, 180, 1-11.	5.0	29
117	Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. <i>Urology</i> , 2017, 99, 155-161.	1.0	17
118	Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. <i>Frontiers in Oncology</i> , 2017, 7, 107.	2.8	44
119	Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 799-806.	2.0	21
120	Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. <i>Molecular Medicine Reports</i> , 2017, 16, 4273-4278.	2.4	14
121	HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4635-4643.	2.0	10
122	GV1001 Induces Apoptosis by Reducing Angiogenesis in Renal Cell Carcinoma Cells Both In Vitro and In Vivo. <i>Urology</i> , 2018, 113, 129-137.	1.0	8
123	Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 88.	2.6	36
124	Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e19-79.e26.	1.6	5
125	Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. <i>Current Oncology</i> , 2018, 25, 576-584.	2.2	16
126	Renal cell carcinoma presenting as nonspecific gastrointestinal symptoms: a case report. <i>International Medical Case Reports Journal</i> , 2018, Volume 11, 345-348.	0.8	2
127	Cytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patientsâ€™ Blood using Hydrogel-based Cell Block Formation. <i>Scientific Reports</i> , 2018, 8, 15218.	3.3	15
128	Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 104, 119-126.	5.6	11
129	PTBP1 knockdown in renal cell carcinoma inhibits cell migration, invasion and angiogenesis in vitro and metastasis in vivo via the hypoxia inducible factor-1 $\alpha$ pathway. <i>International Journal of Oncology</i> , 2018, 52, 1613-1622.	3.3	19



#	ARTICLE	IF	CITATIONS
130	The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 335-343.	0.9	14
131	Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 525-533.	0.9	9
132	SFRP1 Promoter Methylation and Renal Carcinoma Risk: A Systematic Review and Meta-Analysis. <i>Journal of Nippon Medical School</i> , 2018, 85, 78-86.	0.9	10
133	Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. <i>Journal of Medical Economics</i> , 2018, 21, 1150-1158.	2.1	19
134	Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 815-824.	5.0	12
135	Long noncoding RNA HOTAIR promotes renal cell carcinoma malignancy through alpha2,8-sialyltransferase 4 by sponging microRNA-124. <i>Cell Proliferation</i> , 2018, 51, e12507.	5.3	45
136	Comparisons of oncological outcomes and perioperative complications between laparoscopic and open radical nephrectomies in patients with clinical T2 renal cell carcinoma (≤7cm). <i>PLoS ONE</i> , 2018, 13, e0191786.	2.5	4
137	Renal Cell Carcinoma Metastasizing to Left Atrium With Coronary Sinus Invasion: A Rare Site of Metastasis Mimicking Myxoma. <i>Frontiers in Oncology</i> , 2019, 9, 738.	2.8	9
138	Radiation Therapy for Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2019, 3, 1-6.	0.4	2
139	Silencing of the long non-coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial-mesenchymal transition. <i>Oncology Letters</i> , 2019, 17, 3173-3180.	1.8	4
140	Non-Cancer Drug Repurposing Candidates for Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 147-148.	2.0	1
141	Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3300.	3.7	6
142	European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000798.	4.5	6
143	Intradural extramedullary spinal metastasis of renal cell carcinoma: illustrative case report and comprehensive review of the literature. <i>European Spine Journal</i> , 2020, 29, 176-182.	2.2	7
144	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	3.7	15
145	Cell Polarity Protein Pals1-Associated Tight Junction Expression Is a Favorable Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 931.	2.3	6
146	Mandibular swelling as the initial presentation for renal cell carcinoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 70, 96-100.	0.6	4
147	Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151483.	1.3	16

#	ARTICLE	IF	CITATIONS
148	Choice of Surgical Options in Kidney Cancer and Surgical Complications. <i>Seminars in Nephrology</i> , 2020, 40, 42-48.	1.6	10
149	ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner. <i>Cancer Letters</i> , 2020, 482, 74-89.	7.2	19
150	Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells. <i>FEBS Open Bio</i> , 2021, 11, 921-931.	2.3	7
151	SLC39A8/Zinc Suppresses the Progression of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 651921.	2.8	5
152	Identification of a Risk Stratification Model to Predict Overall Survival and Surgical Benefit in Clear Cell Renal Cell Carcinoma With Distant Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 630842.	2.8	8
153	Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-28.	4.0	5
154	Significance of preoperative hematologic scoring in predicting death among patients with non-metastatic renal cell carcinoma undergoing nephrectomy. <i>Asian Journal of Surgery</i> , 2021, 44, 952-956.	0.4	4
156	Population-based evaluation of the risk factors and prognosis among renal cell carcinoma patients with initially diagnosed lung metastases. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 498-506.	0.2	1
157	Axitinib for the Management of Metastatic Renal Cell Carcinoma. <i>Drugs in R and D</i> , 2011, 11, 113-126.	2.2	2
158	Hypoxia and renal cell carcinoma: The influence of HIF1A + 1772C/T functional genetic polymorphism on prognosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e25-532.e30.	1.6	2
159	Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e60483.	2.5	30
160	Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway. <i>PLoS ONE</i> , 2013, 8, e62823.	2.5	121
161	Incidence and mortality of kidney cancers, and human development index in Asia; a matter of concern. <i>Journal of Nephropathology</i> , 2017, 6, 30-42.	0.2	37
162	Chrysophanic Acid Induces Necrosis but not Necroptosis in Human Renal Cell Carcinoma Caki-2 Cells. <i>Journal of Cancer Prevention</i> , 2016, 21, 81-87.	2.0	12
163	Methylation-Based Biomarkers for Early Detection of Urological Cancer. <i>Critical Reviews in Oncogenesis</i> , 2007, 13, 265-282.	0.4	10
164	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	1.8	6
165	Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 68854-68862.	1.8	5
166	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. <i>Oncotarget</i> , 2017, 8, 75076-75086.	1.8	10

#	ARTICLE	IF	CITATIONS
167	Strengthening the foundation of kidney cancer treatment and research: revising the AJCC staging system. <i>Annals of Translational Medicine</i> , 2019, 7, S33-S33.	1.7	10
168	Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 341-348.	2.0	187
170	First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience. <i>Indian Journal of Cancer</i> , 2017, 54, 626.	0.2	5
171	Aberrant Methylation of RASSF1A gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 4665-4669.	1.2	7
173	Quality of Life in Advanced Renal Cell Carcinoma: Effect of Treatment with Cytokine Therapy and Targeted Agents. , 2010, , 2905-2922.		0
174	Erkrankungen der Nieren und Harnwege. , 2011, , 529-606.		0
175	Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. , 2013, , 155-177.		0
176	Clinical Significance of Soluble Major Histocompatibility Complex Class I Chain-related A in Renal Cell Carcinoma Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5651-5655.	1.2	2
177	Quantitative Proteomics Analysis of Differentially Expressed Proteins Involved in Renal Clear Cell Carcinoma by Shotgun Approach Coupled with Stable Isotope Dimethyl Labeling. <i>Journal of Proteomics and Bioinformatics</i> , 2014, s7, .	0.4	1
178	Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 260-264.	0.2	1
179	Bilateral renal cell carcinoma with leiomyomatous stroma: A rare entity diagnosed synchronously and treated surgically in a staged fashion. <i>Turkish Journal of Urology</i> , 2017, 43, 566-570.	1.3	1
180	Microsatellite alteration and metylation of RASSF1 gene in renal cell carcinoma. <i>Faktori Eksperimental Noi Evolucii Organizmiv</i> , 0, 23, 192-196.	0.0	0
181	The Impact of Combination Therapy of Sunitinib with Interferon-Alpha on Survival of Patients with Loco Regional and Metastatic Clear Renal Cell Carcinoma. <i>International Journal of Cancer Management</i> , 2018, In Press, .	0.4	0
182	Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. , 2020, , 411-435.		0
184	Cell-Based Vaccines for Renal Cell Carcinoma. , 2008, , 475-488.		0
185	Management of metastatic renal cell carcinoma in patients with poor prognosis. <i>Cancer Management and Research</i> , 2010, 2, 123-32.	1.9	11
186	Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. <i>Canadian Journal of Urology</i> , 2011, 18, 5819-25.	0.0	17
187	Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM. <i>American Journal of Cancer Research</i> , 2017, 7, 245-259.	1.4	20

#	ARTICLE	IF	CITATIONS
188	Urinary metabolites for urological cancer detection: a review on the application of volatile organic compounds for cancers. American Journal of Clinical and Experimental Urology, 2019, 7, 232-248.	0.4	9
189	Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. Frontiers in Oncology, 2021, 11, 773366.	2.8	5
190	In Silico, In Vitro, and Clinical Investigations of Cathepsin B and Stefin A mRNA Expression and a Correlation Analysis in Kidney Cancer. Cells, 2022, 11, 1455.	4.1	8
191	Renal cell carcinoma with atypical metastases sites revealed by diabetes mellitus: A case report. Annals of Medicine and Surgery, 2022, 81, .	1.1	1
192	Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2023, 50, 311-323.	1.8	2
193	The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer. Urologic Clinics of North America, 2023, 50, 285-303.	1.8	5
194	Parietal Nodular Lesion on The Scalp: Probable Renal Cell Carcinoma Metastasis - A Case Report. Jornal Memorial Da Medicina, 2022, 4, 23-28.	0.2	0
196	The value of EYA1/3/4 in clear cell renal cell carcinoma: a study from multiple databases. Scientific Reports, 2023, 13, .	3.3	0
197	Role of NF- $\kappa$ B pathway in kidney renal clear cell carcinoma and its potential therapeutic implications. Aging, 0, , .	3.1	1
198	Metastatic Renal Cell Carcinoma Presenting as an Intracardiac Tumour Without Involving the Inferior Vena Cava. Cureus, 2023, , .	0.5	0
199	Current status and future perspective of immunotherapy for renal cell carcinoma. International Journal of Clinical Oncology, 0, , .	2.2	0
200	Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers. Chinese Medical Journal, 2014, 127, 1450-1453.	2.3	0
201	Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma. Cellular Oncology (Dordrecht), 0, , .	4.4	0